The company said it plans to implement a significant cost reduction effort in the U.S. to extend its cash runway into 2026 and it will discontinue a second late-stage trial of pamrevlumab for treating IPF.The decision to discontinue the trial came after the drug failed to meet the main goal of achieving a certain change in forced vital capacity, indicating the volume of air a person can exhale in a second and is a key indicator of disease progression, compared to a placebo.
FibroGen's sole commercial product, roxadustat, is approved only in some countries, including China and Japan. The U.S. drug regulator had declined to approve the drug in 2021.Our Standards:
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: